BerGenBio has provided an update from the company’s phase II study of bemcentinib (BGB324), an oral AXL inhibitor, in combination with low-dose cytarabine (LDAC) in elderly AML patients.
The bemcentinib-LDAC combination was safe and well tolerated in elderly AML patients and showed promising efficacy among both newly diagnosed and relapsed/refractory AML patients. The overall response rate and duration surpass historical benchmarks and compare favorably to other LDAC combinations. Pretreatment sAXL holds as a predictive biomarker in AML patients treated with the combination, and a new novel blood based predictive biomarker is identified and associated with clinical benefit in AML and Lung cancer patients receiving bemcentinib.
“This combination trial of bemcentinib with low-dose cytarabine continues to show promising results in AML patients who are unable to tolerate intensive chemotherapy and have limited treatment options. The current data further highlight the novel tumor-immune effects of bemcentinib observed in previous cohorts and in other cancer types. Although these are early findings, we are encouraged by the response rate and duration, and we are focused on advancing our late stage development programme,” says Richard Godfrey, Chief Executive Officer of BerGenBio.
The results were presented in a poster presentation at the 61st Annual American Society of Hematology (ASH) Meeting, being held from 7-10 December in Orlando, Florida.
Photo of Richard Godfrey: Nils Olav Mavatne
